Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis

NCT05194839 is registered in ClinicalTrials.gov with Aristea Therapeutics, Inc. as lead sponsor.

NCT NCT05194839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05194839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
Lead sponsor
Aristea Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 5, 2022
Completion date
March 6, 2023
Enrollment
79 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis